URGN

Urogen Pharma Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 1/10
  • Value↓ 0/10
Urogen Pharma sales and earnings growth
URGN Growth
Low
  • Revenue Y/Y↑ 21.45%
  • EPS Y/Y↓ -7.77%
  • FCF Y/Y↓ -67.66%
Urogen Pharma gross and profit margin trends
URGN Profitability
Fair
  • Gross margin ↑ 88.70%
  • EPS margin↓ -139.80%
  • ROIC 5Y↓ -63.60%
Urogen Pharma net debt vs free cash flow
URGN Risk
Poor
  • Debt / Equity↑ 999.0
  • Debt / FCF↓ 0.1
  • Interest coverage↓ -9.0

Urogen Pharma stock volatility is in-line with the overall market. We give it a Poor risk rating.

More Biotechnology stocks ↗